|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5 Suppl
4:S389–S396. 2013.PubMed/NCBI
|
|
4
|
Li X, Shi Y, Yin Z, Xue X and Zhou B: An
eight-miRNA signature as a potential biomarker for predicting
survival in lung adenocarcinoma. J Transl Med. 12:1592014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naito Y, Kubota K, Nihei K, Fujii T, Yoh
K, Niho S, Goto K, Ohmatsu H, Saijo N and Nishiwaki Y: Concurrent
chemoradiotherapy with cisplatin and vinorelbine for stage III
non-small cell lung cancer. J Thorac Oncol. 3:617–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paz-Ares L, Soulières D, Melezínek I,
Moecks J, Keil L, Mok T, Rosell R and Klughammer B: Clinical
outcomes in non-small-cell lung cancer patients with EGFR
mutations: Pooled analysis. J Cell Mol Med. 14:51–69. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fassina A, Cappellesso R and Fassan M:
Classification of non-small cell lung carcinoma in transthoracic
needle specimens using microRNA expression profiling. Chest.
140:1305–1311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simon J: Technology radiation technology
targets tumors. Surgical precision without the incision. S D Med.
67:3622014.PubMed/NCBI
|
|
9
|
Johtatsu T, Noguchi S, Yatera K, Shinohara
S, Oka S, Yamasaki K, Nishida C, Kawanami T, Kawanami Y, Ishimoto
H, et al: A case of lung adenocarcinoma with uncontrollable
myocardial metastasis and pericardial effusion. J UOEH. 36:199–203.
2014.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilson RC and Doudna JA: Molecular
mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berezikov E, van Tetering G, Verheul M,
van de Belt J, van Laake L, Vos J, Verloop R, van de Wetering M,
Guryev V, Takada S, et al: Many novel mammalian microRNA candidates
identified by extensive cloning and RAKE analysis. Genome Res.
16:1289–1298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fadejeva I, Olschewski H and Hrzenjak A:
MicroRNAs as regulators of cisplatin-resistance in non-small cell
lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lü L, Mao X, Shi P, He B, Xu K, Zhang S
and Wang J: MicroRNAs in the prognosis of triple-negative breast
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 96:e70852017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahir BK, Ozer H, Engelhard HH and Lakka
SS: MicroRNAs in glioblastoma pathogenesis and therapy: A
comprehensive review. Crit Rev Oncol Hematol. 120:22–33. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cortés-Sempere M and de Cáceres Ibáñez I:
microRNAs as novel epigenetic biomarkers for human cancer. Clin
Transl Oncol. 13:357–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo LH, Li H, Wang F, Yu J and He JS: The
tumor suppressor roles of miR-433 and miR-127 in gastric cancer.
Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Mao X, Wang X, Miao G and Li J:
miR-433 reduces cell viability and promotes cell apoptosis by
regulating MACC1 in colorectal cancer. Oncol Lett. 13:81–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP and
Liu LY: MicroRNA-433 inhibits cell proliferation in hepatocellular
carcinoma by targeting p21 activated kinase (PAK4). Mol Cell
Biochem. 399:77–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Tsuchiya H, Zhang Y, Hartnett ME
and Wang L: MicroRNA-433 inhibits liver cancer cell migration by
repressing the protein expression and function of cAMP response
element-binding protein. J Biol Chem. 288:28893–28899. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al Ahmed HA and Nada O: E2F3 transcription
factor: A promising biomarker in lung cancer. Cancer Biomark.
19:21–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cooper CS, Nicholson AG, Foster C, Dodson
A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, et al:
Nuclear overexpression of the E2F3 transcription factor in human
lung cancer. Lung Cancer. 54:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren J, Ding L, Xu Q, Shi G, Li X, Li X, Ji
J, Zhang D, Wang Y, Wang T and Hou Y: LF-MF inhibits iron
metabolism and suppresses lung cancer through activation of
P53-miR-34a-E2F1/E2F3 pathway. Sci Rep. 7:7492017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Li Y, Dong M and Wu D: Long
non-coding RNA NEAT1 regulates E2F3 expression by competitively
binding to miR-377 in non-small cell lung cancer. Oncol Lett.
14:4983–4988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trikha P, Sharma N, Pena C, Reyes A, Pécot
T, Khurshid S, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, et
al: E2f3 in tumor macrophages promotes lung metastasis. Oncogene.
35:3636–3646. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao D, Han W, Liu X, Cui D and Chen Y:
MicroRNA-128 promotes apoptosis in lung cancer by directly
targeting NIMA-related kinase 2. Thorac Cancer. 8:304–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao X, Lu C, Chu W, Zhang B, Zhen Q, Wang
R, Zhang Y, Li Z, Lv B, Li H and Liu J: MicroRNA-124 suppresses
proliferation and glycolysis in non-small cell lung cancer cells by
targeting AKT-GLUT1/HKII. Tumour Biol. 39:10104283177062152017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Castro D, Moreira M, Gouveia AM, Pozza DH
and De Mello RA: MicroRNAs in lung cancer. Oncotarget.
8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin X, Rice KL, Buzzai M, Hexner E, Costa
FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R and
Licht JD: miR-433 is aberrantly expressed in myeloproliferative
neoplasms and suppresses hematopoietic cell growth and
differentiation. Leukemia. 27:344–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang XC, Ma Y, Meng PS, Han JL, Yu HY and
Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell
growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang T, Guo Q, Li L, Cheng Y, Ren C and
Zhang G: MicroRNA-433 inhibits migration and invasion of ovarian
cancer cells via targeting Notch1. Neoplasma. 63:696–704. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li X, Yang L, Shuai T, Piao T and Wang R:
MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1
and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun S, Wang X, Xu X, Di H, Du J, Xu B,
Wang Q and Wang J: MiR-433-3p suppresses cell growth and enhances
chemosensitivity by targeting CREB in human glioma. Oncotarget.
8:5057–5068. 2017.PubMed/NCBI
|
|
39
|
Sun Y, Wang F, Wang L, Jiao Z, Fang J and
Li J: MicroRNA-433 regulates apoptosis by targeting PDCD4 in human
osteosarcoma cells. Oncol Lett. 14:2353–2358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Olsson AY, Feber A, Edwards S, Te Poele R,
Giddings I, Merson S and Cooper CS: Role of E2F3 expression in
modulating cellular proliferation rate in human bladder and
prostate cancer cells. Oncogene. 26:1028–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo Y, Qi Y, Guo A, Du C, Zhang R and Chu
X: miR-564 is downregulated in gastric carcinoma and targets E2F3.
Oncol Lett. 13:4155–4160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang SW, Yue J, Wang BC and Zhang XL:
miR-503 inhibits cell proliferation and induces apoptosis in
colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol.
8:12853–12860. 2015.PubMed/NCBI
|
|
43
|
Lee M, Oprea-Ilies G and Saavedra HI:
Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer
cells by restricting mitosis. Oncotarget. 6:37316–37334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang JP, Jiao Y, Wang CY, Xu ZB and Zhang
B: Rb knockdown accelerates bladder cancer progression through E2F3
activation. Int J Oncol. 50:149–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oeggerli M, Tomovska S, Schraml P,
Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ and
Sauter G: E2F3 amplification and overexpression is associated with
invasive tumor growth and rapid tumor cell proliferation in urinary
bladder cancer. Oncogene. 23:5616–5623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dong D, Gong Y, Zhang D, Bao H and Gu G:
miR-874 suppresses the proliferation and metastasis of osteosarcoma
by targeting E2F3. Tumour Biol. 37:6447–6455. 2016. View Article : Google Scholar : PubMed/NCBI
|
